Insulin degludec and liraglutide and Thyroid carcinoma
Result of checking the interaction of drug Insulin degludec and liraglutide and disease Thyroid carcinoma for safety when used together.
When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.
Consumer:GLP-1 receptor agonist antidiabetic drugs are contraindicated in patients with a personal or family history of medullary thyroid carcinoma and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Carcinogenicity studies in rodents and limited postmarketing data suggest that GLP-1 inhibitors may cause a dose-related and treatment duration-related increase in risk of thyroid C-cell tumors, although a causal relationship has not been established.
Generic Name: insulin degludec / liraglutide
Brand Name: Xultophy
Synonyms: Insulin Degludec and Liraglutide
Insulin degludec and liraglutide - rak tarczycy 
Insulin degludec and liraglutide - carcinoma de tireoide 
Insulin degludec and liraglutide - karsinoma tiroid 
Insulin degludec and liraglutide - karsinoma tiroid 
Insulin degludec and liraglutide - carcinoma della tiroide 
Insulin degludec and liraglutide - carcinome thyroïdien 
Insulin degludec and liraglutide - Schilddrüsenkarzinom 
Insulin degludec and liraglutide - carcinoma de tiroides 
Insulin degludec and liraglutide - карцинома щитовидной железы 
Insulin degludec and liraglutide - tiroid karsinomu 
Insulin degludec and liraglutide - سرطان الغدة الدرقية 
Insulin degludec and liraglutide - 甲状腺癌